Biotronik, a medical device manufacturer based in Germany, announced that a clinical study of the company’s ICD home monitoring system shows that the device can reduce unnecessary shocks by 50 percent. By reducing the number of shocks administered to a patient, it’s possible to improve system efficacy, battery life and safety.
The study, dubbed the Effectiveness and Cost of ICD Follow-UP Schedule with Telecardiology (ECOST) trial, showed that inappropriate shocks by an implanted cardioverter defibrillator were decreased by 52 percent. This process also led to battery life increases for the defibrillator unit itself.
The study comprised 433 patients at 43 different sites around France. These patients were followed for 27 months. Of these patients, 221 were home-monitored. The rest of the patients acted as controls. Researchers found that patients with home monitoring experienced 71 percent fewer shocks on average over two years. Compared to the control group, the device delivered 52 percent less unnecessary shocks.
The study also showed that there was a 76 percent reduction in total device capacitor charges in the home monitoring group. This reduction in total device capacitor charges has the potential to increase ICD battery life in the future.
Christoph Bohmer is international president of Biotronik. In prepared remarks, he said, "Developing safe, innovative, effective therapies to improve patient health is Biotronik's number 1 priority." He continued, "Biotronik Home Monitoring enhances the patient's quality of life and simplifies patient treatment."